Beta2-adrenergic Agonism and Muscle Remodelling

Morten Hostrup, PhD

Status: Unknown

Conditions: Physiologic Hypertrophy; Physical Activity; Hypertrophy

Treatments: Drug: Formoterol; Other: Placebo; Drug: Terbutaline

Study type: Interventional

Funder types: Other

Identifiers

NCT03565302

FOR/TER

Details and patient eligibility

About

The study aims to investigate gender-specific adaptations to beta2-adrenoceptor stimulation with selective short- and long-acting beta2-agonist with emphasis on skeletal muscle in relation to performance enhancing effects and anti-doping

Enrollment: 72 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy men and women, aged 18-45 years
• VO2max >55 ml/kg/min for men and >50 ml/kg/min for women (± biologic and techinical variation of 5.6% (Katch et al. 1982)
• Body Mass Index (BMI) < 26

Exclusion criteria

• Chronic user of beta2-agonist or allergy towards study drugs
• Serious adverse side effects of the used study drug
• Chronic disease that by the project physician would affect any of the outcomes of the study
• Smoker
• Chronic use of prescription medication (other than contraceptives for women)
• Pregnancy

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

72 participants in 3 patient groups, including a placebo group

Control

Placebo Comparator group

Description:

Subjects receive placebo treatment

Treatment:

Other: Placebo

Long acting beta2-agonist

Experimental group

Description:

Subjects are treated with long-acting beta2-agonist formoterol

Treatment:

Drug: Formoterol

Short acting beta2-agonist

Experimental group

Description:

Subjects are treated with short-acting beta2-agonist terbutaline

Treatment:

Drug: Terbutaline